INTEGRA LIFESCIENCES HOLDING (IART)
US4579852082 - Common Stock
We assign a fundamental rating of 4 out of 10 to IART. IART was compared to 188 industry peers in the Health Care Equipment & Supplies industry. IART has a medium profitability rating, but doesn't score so well on its financial health evaluation. A decent growth rate in combination with a cheap valuation! Better keep an eye on IART.
1. Profitability
1.1 Basic Checks
IART had positive earnings in the past year.
IART had a positive operating cash flow in the past year.
IART had positive earnings in each of the past 5 years.
Each year in the past 5 years IART had a positive operating cash flow.
1.2 Ratios
IART has a better Return On Assets (-0.16%) than 69.52% of its industry peers.
Looking at the Return On Equity, with a value of -0.43%, IART is in the better half of the industry, outperforming 70.59% of the companies in the same industry.
With a decent Return On Invested Capital value of 4.93%, IART is doing good in the industry, outperforming 78.07% of the companies in the same industry.
IART had an Average Return On Invested Capital over the past 3 years of 6.75%. This is in line with the industry average of 8.23%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.16% | ||
| ROE | -0.43% | ||
| ROIC | 4.93% |
ROA(3y)3.63%
ROA(5y)3.23%
ROE(3y)8.1%
ROE(5y)7.34%
ROIC(3y)6.75%
ROIC(5y)6.66%
1.3 Margins
IART's Profit Margin has been stable in the last couple of years.
IART has a better Operating Margin (11.84%) than 80.21% of its industry peers.
IART's Operating Margin has improved in the last couple of years.
IART has a Gross Margin (59.29%) which is in line with its industry peers.
In the last couple of years the Gross Margin of IART has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.84% | ||
| PM (TTM) | N/A | ||
| GM | 59.29% |
OM growth 3Y3.4%
OM growth 5Y2.16%
PM growth 3Y-23.36%
PM growth 5Y1.25%
GM growth 3Y-0.76%
GM growth 5Y-0.14%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IART is destroying value.
The number of shares outstanding for IART has been reduced compared to 1 year ago.
The number of shares outstanding for IART has been reduced compared to 5 years ago.
The debt/assets ratio for IART is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.32, we must say that IART is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of 1.32, IART perfoms like the industry average, outperforming 51.34% of the companies in the same industry.
The Debt to FCF ratio of IART is 47.52, which is on the high side as it means it would take IART, 47.52 years of fcf income to pay off all of its debts.
IART has a Debt to FCF ratio of 47.52. This is in the better half of the industry: IART outperforms 67.38% of its industry peers.
IART has a Debt/Equity ratio of 0.79. This is a neutral value indicating IART is somewhat dependend on debt financing.
IART has a worse Debt to Equity ratio (0.79) than 74.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | 47.52 | ||
| Altman-Z | 1.32 |
ROIC/WACC0.64
WACC7.69%
2.3 Liquidity
A Current Ratio of 1.20 indicates that IART should not have too much problems paying its short term obligations.
IART has a worse Current ratio (1.20) than 86.63% of its industry peers.
A Quick Ratio of 0.73 indicates that IART may have some problems paying its short term obligations.
With a Quick ratio value of 0.73, IART is not doing good in the industry: 90.91% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.73 |
3. Growth
3.1 Past
IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.27%.
Measured over the past 5 years, IART shows a small growth in Earnings Per Share. The EPS has been growing by 5.08% on average per year.
IART shows a small growth in Revenue. In the last year, the Revenue has grown by 1.45%.
The Revenue has been growing slightly by 0.92% on average over the past years.
EPS 1Y (TTM)-21.27%
EPS 3Y8.16%
EPS 5Y5.08%
EPS Q2Q%-46.05%
Revenue 1Y (TTM)1.45%
Revenue growth 3Y3.96%
Revenue growth 5Y0.92%
Sales Q2Q%-0.93%
3.2 Future
The Earnings Per Share is expected to grow by 13.76% on average over the next years. This is quite good.
Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 5.95% on average per year.
EPS Next Y-19.53%
EPS Next 2Y-9.2%
EPS Next 3Y-2.95%
EPS Next 5Y13.76%
Revenue Next Year4.44%
Revenue Next 2Y5.26%
Revenue Next 3Y5.01%
Revenue Next 5Y5.95%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 9.27, the valuation of IART can be described as very reasonable.
Based on the Price/Earnings ratio, IART is valued cheaper than 97.86% of the companies in the same industry.
IART is valuated cheaply when we compare the Price/Earnings ratio to 28.96, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 9.00 indicates a reasonable valuation of IART.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IART indicates a rather cheap valuation: IART is cheaper than 98.93% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.82. IART is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.27 | ||
| Fwd PE | 9 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IART is valued cheaper than 95.19% of the companies in the same industry.
IART's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IART is cheaper than 78.07% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 46.68 | ||
| EV/EBITDA | 10.13 |
4.3 Compensation for Growth
IART has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as IART's earnings are expected to decrease with -2.95% in the coming years.
PEG (NY)N/A
PEG (5Y)1.83
EPS Next 2Y-9.2%
EPS Next 3Y-2.95%
5. Dividend
5.1 Amount
No dividends for IART!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTEGRA LIFESCIENCES HOLDING
NASDAQ:IART (11/21/2024, 8:00:02 PM)
After market: 23.35 +0.35 (+1.52%)23
+0.07 (+0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.77B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.27 | ||
| Fwd PE | 9 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)1.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.16% | ||
| ROE | -0.43% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 11.84% | ||
| PM (TTM) | N/A | ||
| GM | 59.29% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.38
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.79 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.2 | ||
| Quick Ratio | 0.73 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-21.27%
EPS 3Y8.16%
EPS 5Y
EPS Q2Q%
EPS Next Y-19.53%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)1.45%
Revenue growth 3Y3.96%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y